We are thrilled to share an exciting update on our novel technology in regenerative medicine and its use in orthopaedics! At Theragenix, we're committed to making science and its outcomes more accessible. 🎥 We've just released a video showcasing our innovative approach, designed for a general audience. Watch it here: https://lnkd.in/gQU2-EDF 🧬 For those interested in scientific jargon, visit our newly updated website at www.theragenix.health for viewing the video with a different script! 🚀 We're currently in a fundraising round to accelerate our development. If you're an investor interested in our work, We'd love to connect! #regenerativemedicine #orthopaedics #innovation #fundraising #biotech #genetherapy #innovateUK Anand Nandakumar Ph.D Stefania Fedele Gina Melchner von Dydiowa Nina Lameule Alice MacGowan NLC Health VenturesNottingham Technology Ventures Ltd
About us
TherageniX is an early-stage biotechnology company pioneering the use of gene therapy for tissue regeneration. Initially, it aims to augment autologous bone grafts using its proprietary technology to promote regenerative capacity, improve functional outcomes, and reduce additional trauma at the donor site. Transplantation of autologous bone is still the gold standard bone repair strategy, with 4 million grafting procedures performed annually worldwide. However, many bone implants still fail due to rejection or infection or fail to provide satisfactory functionality and regeneration. TherageniX is uniquely positioned to address the growing needs of the global bone grafts and substitutes market. TherageniX, a healthcare start-up built by NLC—the European healthtech venture builder, licensed the technology from Dr James Dixon’s group at the University of Nottingham and was incorporated in 2022 with the support of Nottingham Technology Ventures Ltd.
- Website
-
https://theragenix.health/
External link for TherageniX
- Industry
- Biotechnology Research
- Company size
- 1 employee
- Type
- Privately Held
- Founded
- 2022
- Specialties
- gene therapy, tissue regeneration, orthopaedic, bone, bone grafts, healthcare, biotechnology, tissue repair, atmp, and biologics
Employees at TherageniX
Updates
-
We happy and thrilled to share that Prof. Laurencin, a pioneer in the field of regenerative engineering has joined the Scientific Advisory Board at TherageniX. Looking forward to working with him to bring our novel therapy to patients in need. You can read more here: https://lnkd.in/ecCWnsEY NLC Health Ventures Gina MelchnerNottingham Technology Ventures Ltd
-
Publication alert! Do have a look at the article that Dr. James Dixon and I wrote about non-viral gene delivery for orthopaedic applications published in the Innovations in Pharmaceutical Technology (IPT). NLC Health Ventures Nottingham Technology Ventures Ltd https://lnkd.in/ernSDUuZ
Non-viral gene therapies: GETting growth-factor-based healing right in orthopaedics
https://theragenix.health
-
More news from our side! We are delighted to strengthen our team further with Stefania joining us in January as a Scientific Project Manager. Stefania is a biologist with a post-doc qualification and several years of experience in the biotech industry, specialising in the development of innovative cell and gene therapies for rare diseases, neurodegeneration, cancer and immunology. Please join me in welcoming Stefania and wishing her success in her role.
-
It's a new year and we have some news to share. We are very happy that Prof. Ollivere has joined as the first member of our Scientific Advisory Board! Prof. Ollivere is an orthopaedic surgeon, researcher and academic who also has the experience of bringing innovations to the market. Really excited to have him on board! Welcome Ben Ollivere! https://lnkd.in/gmJHHDpm
TherageniX appoints Professor Ben Ollivere to its Scientific Advisory Board
https://theragenix.health